Porton Pharma Solutions (300363.SZ) announced its 2024 interim report on August 27th. During the reporting period, the revenue was 1.352 billion yuan, a decrease of 42.19% year-on-year; the net income attributable to shareholders of the listed company was -0.17 billion yuan, turning from profit to loss year-on-year; the net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was -0.174 billion yuan; and the basic earnings per share was -0.31 yuan.
博腾股份(300363.SZ)：上半年净亏损1.70亿元 同比盈转亏
Porton Pharma Solutions (300363.SZ): Net loss of 0.17 billion yuan in the first half of the year, turning from profit to loss year-on-year.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated